EYPT

EyePoint Pharmaceuticals, Inc. [EYPT] Stock Forecast

Q: What is EyePoint Pharmaceuticals, Inc. stock symbol ?

EyePoint Pharmaceuticals, Inc. is a US stock, located in Watertown of Ma and trading under the symbol EYPT

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

EYPT Stock Summary

Earnings have grown 12.09% per last year.

Earnings are expected to fall -18.39% next year

Currently unprofitable, and not expected to turn profitable in the coming year

Top EYPT Correlated Resources

EYPT

Top 10 Correlated ETFs

EYPT

Top 10 Correlated Stocks

EYPT

In the News

08:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

07:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments.

01:33 22 Mar 2023 EYPT

5 Penny Stocks To Buy According To Analysts, Targets Up To 992%

Analysts say these are penny stocks to buy. Do you agree?

08:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

01:58 22 Mar 2023 EYPT

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:13 AM ET EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q3 2022 Earnings Conference Call November 02, 2022, 08:30 AM ET Company Participants Nancy Lurker - President and CEO George Elston - CFO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen Yi Chen - H.C. Wainwright Yale Jen - Laidlaw & Company Daniil Gatualin - Chardan Yuan Zhi - B.

09:48 22 Mar 2023 EYPT

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

07:00 22 Mar 2023 EYPT

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments.

04:01 22 Mar 2023 EYPT

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

12:17 22 Mar 2023 EYPT

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Shares have lost 15% year to date. Durasert technology has been extensively validated and administered to over 80,000 patient eyes.

03:05 22 Mar 2023 EYPT

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and Chief Executive Officer Jay Duker - Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Jennifer Kim - Cantor Yale Jen - Laidlaw Yi Chen - H.C. Wainwright Operator Good morning.

EYPT Financial details

Company Rating

Neutral

Market Cap

80.09M

Income

-102.25M

Revenue

41.4M

Book val./share

2.58

Cash/share

3.87

Dividend

Dividend %

Employees

122

Optionable

Shortable

Yes

Earnings

02 May 2023

P/E

-1.21

Forward P/E

PEG

0.3

P/S

2.24

P/B

0.7

P/C

0.66

P/FCF

-1.24

Quick Ratio

5.2

Current Ratio

5.61

Debt / Equity

0.87

LT Debt / Equity

0.37

EPS (TTM)

-2.73

EPS next Y

EPS next Q

-0.56

EPS this Y

-39.79%

EPS next Y

EPS next 5Y

-37.18%

EPS last 5Y

-24.94%

Revenue last 5Y

69.48%

Revenue Q/Q

5.2%

EPS Q/Q

136.73%

SMA20

-50%

SMA50

-33.33%

SMA100

-66.67%

Inst Own

78.66%

Inst Trans

-1.95%

ROA

-35%

ROE

-49%

ROC

-0.4%

Gross Margin

81%

Oper. Margin

-174%

Profit Margin

-184%

Payout

Shs Outstand

34.3M

Shs Float

18.09M

Target Price

52W Range

2.19-13.63

52W High

-80.42%

52W Low

+27.25%

RSI

Rel Volume

0.65

Avg Volume

284.51K

Volume

185.81K

Perf Week

-0.97%

Perf Month

-43.94%

Perf Quarter

-66.73%

Perf Half Y

-67.29%

Beta

1.03963

Volatility

0.08%, 0.59%

Prev Close

Price

2.545

Change

2.21%

EYPT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-06-30	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0.64	1.95	2.68	2.88	1.11
Net income per share	-11.5	-5.44	-3.54	-4.55	-2.74
Operating cash flow per share	-4.74	-5.44	-1.12	-3.9	-1.74
Free cash flow per share	-4.76	-5.46	-1.15	-3.92	-1.8
Cash per share	8.39	2.13	3.5	16.48	3.87
Book value per share	2.53	0.8	1.44	14.36	2.58
Tangible book value per share	-4.26	-1.85	-0.52	12.59	2.58
Share holders equity per share	2.53	0.8	1.44	14.36	2.58
Interest debt per share	3.9	5.44	3.71	3.48	1.31
Market cap	96.15M	161.68M	84.46M	157.11M	130.61M
Enterprise value	74.68M	190.06M	79.86M	17.72M	80.75M
P/E ratio	-1.81	-2.85	-1.86	-2.69	-1.28
Price to sales ratio	32.47	7.94	2.45	4.25	3.15
POCF ratio	-4.39	-2.85	-5.85	-3.14	-2.01
PFCF ratio	-4.37	-2.84	-5.71	-3.13	-1.94
P/B Ratio	8.23	19.41	4.56	0.85	1.36
PTB ratio	8.23	19.41	4.56	0.85	1.36
EV to sales	25.22	9.33	2.32	0.48	1.95
Enterprise value over EBITDA	-1.46	-3.96	-2.25	-0.35	-0.83
EV to operating cash flow	-3.41	-3.35	-5.53	-0.35	-1.24
EV to free cash flow	-3.39	-3.34	-5.4	-0.35	-1.2
Earnings yield	-0.55	-0.35	-0.54	-0.37	-0.78
Free cash flow yield	-0.23	-0.35	-0.18	-0.32	-0.51
Debt to equity	5.13	7.76	3.95	0.43	0.87
Debt to assets	0.84	0.89	0.8	0.3	0.47
Net debt to EBITDA	0.42	-0.59	0.13	2.78	0.51
Current ratio	1.84	3.62	4.24	10.05	5
Interest coverage	-36.49	-7.75	-5.14	-10.05	-31.24
Income quality	0.41	1	0.32	0.86	0.64
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.9	0.88	0.6	0.69	0.84
Research and developement to revenue	5.46	0.75	0.51	0.77	1.2
Intangibles to total assets	0.44	0.38	0.27	0.09	0
Capex to operating cash flow	0	0	0.03	0	0.03
Capex to revenue	-0.04	-0.01	-0.01	0	-0.05
Capex to depreciation	-0.09	-0.08	-0.14	-0.06	-1.05
Stock based compensation to revenue	0.91	0.22	0.16	0.2	0.34
Graham number	25.58	9.89	10.72	38.35	12.62
ROIC	2.98	-1.97	12.81	0.55	5.92
Return on tangible assets	-1.32	-1.25	-0.68	-0.24	-0.57
Graham Net	-4.53	-3.15	-1.44	11.54	1.97
Working capital	18.25M	30.2M	48.23M	214.09M	138.27M
Tangible asset value	-19.67M	-19.34M	-6.67M	161.63M	96.37M
Net current asset value	-20.07M	-22.92M	-10.06M	158.75M	88.82M
Invested capital	1.48	6.07	2.17	0.21	0.47
Average receivables	302K	5.86M	10.41M	13.9M	16.93M
Average payables	1.98M	3.57M	4.5M	6.1M	6.65M
Average inventory	0	1.07M	3.74M	4.48M	3.25M
Days sales outstanding	43.51	203.75	100.19	181.36	136.67
Days payables outstanding	0	569.44	301.51	329.65	259.48
Days of inventory on hand	0	290.42	334.48	161.41	126.52
Receivables turnover	8.39	1.79	3.64	2.01	2.67
Payables turnover	0	0.64	1.21	1.11	1.41
Inventory turnover	0	1.26	1.09	2.26	2.88
ROE	-4.55	-6.82	-2.45	-0.32	-1.06
Capex per share	-0.02	-0.02	-0.03	-0.01	-0.06

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0.35	0.25	0.31	0.27	0.28
Net income per share	-0.59	-0.56	-0.52	-0.49	-1.16
Operating cash flow per share	-0.51	-0.54	-0.51	-0.35	-0.34
Free cash flow per share	-0.51	-0.55	-0.52	-0.38	-0.35
Cash per share	6.47	5.12	4.59	4.21	3.87
Book value per share	5.64	4.48	4.06	3.65	2.58
Tangible book value per share	4.94	3.88	3.48	3.09	2.58
Share holders equity per share	5.64	4.48	4.06	3.65	2.58
Interest debt per share	1.24	1.14	1.21	1.26	1.25
Market cap	400.25M	452.62M	293.72M	295.34M	130.61M
Enterprise value	260.86M	392.36M	256.07M	266.44M	80.75M
P/E ratio	-5.15	-5.39	-3.78	-4.01	-0.75
Price to sales ratio	34.67	48.7	25.4	29.5	12.4
POCF ratio	-24.01	-22.45	-15.36	-22.48	-10.38
PFCF ratio	-24.01	-22.29	-15.19	-20.6	-9.91
P/B Ratio	2.17	2.71	1.94	2.17	1.36
PTB ratio	2.17	2.71	1.94	2.17	1.36
EV to sales	22.6	42.22	22.14	26.61	7.67
Enterprise value over EBITDA	-15.04	-20.56	-14.11	-15.63	-1.89
EV to operating cash flow	-15.65	-19.46	-13.39	-20.28	-6.41
EV to free cash flow	-15.65	-19.32	-13.24	-18.59	-6.13
Earnings yield	-0.05	-0.05	-0.07	-0.06	-0.33
Free cash flow yield	-0.04	-0.04	-0.07	-0.05	-0.1
Debt to equity	0.43	0.47	0.54	0.62	0.87
Debt to assets	0.3	0.32	0.35	0.38	0.47
Net debt to EBITDA	8.04	3.16	2.07	1.7	1.17
Current ratio	10.05	6.87	6.17	5.61	5
Interest coverage	-13	-15.31	-34.81	-27.79	-56
Income quality	0.86	0.96	0.99	0.71	0.29
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.8	0.92	0.74	0.92	0.81
Research and developement to revenue	0.77	1.07	1.12	1.11	1.48
Intangibles to total assets	0.09	0.09	0.09	0.09	0
Capex to operating cash flow	0	0.01	0.01	0.09	0.05
Capex to revenue	0	-0.02	-0.02	-0.12	-0.06
Capex to depreciation	0	-0.21	-0.31	-1.68	9.59
Stock based compensation to revenue	0.24	0.37	0.36	0.32	0.32
Graham number	8.68	7.53	6.89	6.37	8.23
ROIC	0.18	-0.54	-0.31	-0.29	2.6
Return on tangible assets	-0.08	-0.09	-0.09	-0.09	-0.24
Graham Net	4.53	3.47	2.88	2.42	1.97
Working capital	214.09M	187.66M	172.48M	157.85M	138.27M
Tangible asset value	161.63M	144.69M	129.85M	115.45M	96.37M
Net current asset value	158.75M	141.89M	123.8M	107.96M	88.82M
Invested capital	0.21	0.25	0.29	0.34	0.47
Average receivables	15.98M	18.97M	21.09M	21.74M	18.19M
Average payables	7.01M	7.34M	7.18M	6.59M	6.02M
Average inventory	4.09M	3.48M	3.3M	3.39M	3.21M
Days sales outstanding	143.09	189.69	175.83	187.66	132.47
Days payables outstanding	219.14	369.83	366.33	391.52	156.22
Days of inventory on hand	107.3	168.96	168.89	226.19	76.17
Receivables turnover	0.63	0.47	0.51	0.48	0.68
Payables turnover	0.41	0.24	0.25	0.23	0.58
Inventory turnover	0.84	0.53	0.53	0.4	1.18
ROE	-0.11	-0.13	-0.13	-0.14	-0.45
Capex per share	0	0	-0.01	-0.03	-0.02

EYPT Frequently Asked Questions

What is EyePoint Pharmaceuticals, Inc. stock symbol ?

EyePoint Pharmaceuticals, Inc. is a US stock , located in Watertown of Ma and trading under the symbol EYPT

Is EyePoint Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $25. The lowest prediction is $25 and the highest is $25

What is EYPT stock prediction ?

What is EyePoint Pharmaceuticals, Inc. stock quote today ?

EyePoint Pharmaceuticals, Inc. stock price is $2.545 today.

Is EyePoint Pharmaceuticals, Inc. stock public?

Yes, EyePoint Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 284.51K
Market Capitalization 80.09M
Employee 122
CEO Ms. Nancy S. Lurker
Headquarters Watertown,MA,US
IPO Date 2005-01-27
Website https://eyepointpharma.com

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.